Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interrogating Adaptive Immunity Using LCMV.

Literature DB >> 32940427

Interrogating Adaptive Immunity Using LCMV.

Tanushree Dangi¹, Young Rock Chung¹, Nicole Palacio¹, Pablo Penaloza-MacMaster¹.

Abstract

In this invited article, we explain technical aspects of the lymphocytic choriomeningitis virus (LCMV) system, providing an update of a prior contribution by Matthias von Herrath and J. Lindsay Whitton. We provide an explanation of the LCMV infection models, highlighting the importance of selecting an appropriate route and viral strain. We also describe how to quantify virus-specific immune responses, followed by an explanation of useful transgenic systems. Specifically, our article will focus on the following protocols.

© 2020 Wiley Periodicals LLC. Basic Protocol 1: LCMV infection routes in mice Support Protocol 1: Preparation of LCMV stocks ASSAYS TO MEASURE LCMV TITERS Support Protocol 2: Plaque assay Support Protocol 3: Immunofluorescence focus assay (IFA) to measure LCMV titer MEASUREMENT OF T CELL AND B CELL RESPONSES TO LCMV INFECTION Basic Protocol 2: Triple tetramer staining for detection of LCMV-specific CD8 T cells Basic Protocol 3: Intracellular cytokine staining (ICS) for detection of LCMV-specific T cells Basic Protocol 4: Enumeration of direct ex vivo LCMV-specific antibody-secreting cells (ASC) Basic Protocol 5: Limiting dilution assay (LDA) for detection of LCMV-specific memory B cells Basic Protocol 6: ELISA for quantification of LCMV-specific IgG antibody Support Protocol 4: Preparation of splenic lymphocytes Support Protocol 5: Making BHK21-LCMV lysate Basic Protocol 7: Challenge models TRANSGENIC MODELS Basic Protocol 8: Transfer of P14 cells to interrogate the role of IFN-I on CD8 T cell responses Basic Protocol 9: Comparing the expansion of naïve versus memory CD4 T cells following chronic viral challenge. © 2020 Wiley Periodicals LLC.

Entities: Chemical

Keywords: LCMV model; acute viral infection; chronic viral infection; immune exhaustion; immune memory

Mesh：

Substances：

Year: 2020 PMID： 32940427 PMCID： PMC9284604 DOI： 10.1002/cpim.99

Source DB: PubMed Journal: Curr Protoc Immunol ISSN： 1934-3671

49 in total

1. Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

Authors: Mitra Bhattacharyya; Pablo Penaloza-MacMaster
Journal: AIDS Res Hum Retroviruses Date: 2018-04-18 Impact factor: 2.205

2. Humoral immunity due to long-lived plasma cells.

Authors: M K Slifka; R Antia; J K Whitmire; R Ahmed
Journal: Immunity Date: 1998-03 Impact factor: 31.745

3. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.

Authors: A Oxenius; M F Bachmann; R M Zinkernagel; H Hengartner
Journal: Eur J Immunol Date: 1998-01 Impact factor: 5.532

4. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.

Authors: Vaiva Vezys; Pablo Penaloza-MacMaster; Daniel L Barber; Sang-Jun Ha; Bogumila Konieczny; Gordon J Freeman; Robert S Mittler; Rafi Ahmed
Journal: J Immunol Date: 2011-07-08 Impact factor: 5.422

5. Type I interferon suppresses virus-specific B cell responses by modulating CD8⁺ T cell differentiation.

Authors: E Ashley Moseman; Tuoqi Wu; Juan Carlos de la Torre; Pamela L Schwartzberg; Dorian B McGavern
Journal: Sci Immunol Date: 2016-10-21

6. Antiviral immune responses of lymphocytic choriomeningitis virus-infected mice lacking CD8+ T lymphocytes because of disruption of the beta 2-microglobulin gene.

Authors: F Lehmann-Grube; J Löhler; O Utermöhlen; C Gegin
Journal: J Virol Date: 1993-01 Impact factor: 5.103

7. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Authors: Se Jin Im; Masao Hashimoto; Michael Y Gerner; Junghwa Lee; Haydn T Kissick; Matheus C Burger; Qiang Shan; J Scott Hale; Judong Lee; Tahseen H Nasti; Arlene H Sharpe; Gordon J Freeman; Ronald N Germain; Helder I Nakaya; Hai-Hui Xue; Rafi Ahmed
Journal: Nature Date: 2016-08-02 Impact factor: 49.962

8. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.

Authors: Pablo Penaloza-MacMaster; Alice O Kamphorst; Andreas Wieland; Koichi Araki; Smita S Iyer; Erin E West; Leigh O'Mara; Shu Yang; Bogumila T Konieczny; Arlene H Sharpe; Gordon J Freeman; Alexander Y Rudensky; Rafi Ahmed
Journal: J Exp Med Date: 2014-08-11 Impact factor: 14.307

Interrogating Adaptive Immunity Using LCMV.

1. Dynamics of Lymphocyte Reconstitution After Hematopoietic Transplantation During Chronic Lymphocytic Choriomeningitis Virus Infection.

2. Humoral immunity due to long-lived plasma cells.

3. Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection.

4. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.

5. Type I interferon suppresses virus-specific B cell responses by modulating CD8⁺ T cell differentiation.

6. Antiviral immune responses of lymphocytic choriomeningitis virus-infected mice lacking CD8+ T lymphocytes because of disruption of the beta 2-microglobulin gene.

7. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

8. Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection.

9. TLR4 signaling improves PD-1 blockade therapy during chronic viral infection.

10. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

1. CXCL10 chemokine regulates heterogeneity of the CD8⁺ T cell response and viral set point during chronic infection.

2. Cross-protective immunity following coronavirus vaccination and coronavirus infection.

3. A CD4⁺ T cell reference map delineates subtype-specific adaptation during acute and chronic viral infections.

4. Pre-existing immunity modulates responses to mRNA boosters.

5. Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity.

6. Early type I IFN blockade improves the efficacy of viral vaccines.

7. Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity.

8. Adoptive B cell therapy for chronic viral infection.

Review 9. Lymphocytic Choriomeningitis-Emerging Trends of a Neglected Virus: A Narrative Review.